510(k) SUMMARY

Submitted by

3.0

Synovis Surgical Innovations

A Division of Synovis Life Technologies, Inc.

2575 University Ave. W. St. Paul, MN 55114 Tel: 651-603-3700 Fax: 651-603-5211

Contact Person

Angela Mallery

At address above

Device Trade Name: Peri-Strips® Staple Line Reinforcement – Sleeve Configuration

Peri-Strips® Staple Line Reinforcement – Strip Configuration

Peri-Strips® Dry Staple Line Reinforcement

Common Name

Surgical Mesh

Classification Name Mesh, Surgical

878.3300

Predicate device

Peri-Strips® Staple Line Reinforcement (Synovis Surgical

Innovations, a division of Synovis Life Technologies, Inc.) -

K983162

SEAMGUARD® Bioabsorbable Staple Line Reinforcement

Material (W.L. Gore & Associates, Inc., Flagstaff, AZ)

K.032865

Device Description

An implantable surgical patch comprised of crosslinked bovine

pericardium

Statement of Intended use

Peri-Strips Staple Line Reinforcement is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers when staple line reinforcement is needed.

Peri-Strips can be used for reinforcement of staple lines during lung and bronchus resections and during bariatric surgical procedures.

Peri-Strips can also be used for reinforcement of staple lines during gastric, small bowel, mesentery, colon, and colorectal procedures.

Technological Comparisons

Peri-Strips® Staple Line Reinforcement is substantially equivalent to the predicate device, having the same technological characteristics.

Testing

Peri-Strips® Staple Line Reinforcement is substantially equivalent to the predicate device in term of testing and indications for use.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 1 7 2004

Ms. Angela Mallery Regulatory Affairs Manager Synovis Life Technologies, Inc. 2575 University Avenue W. St. Paul, Minnesota 55114

Re: K040119

Trade/Device Name: Peri-Strips Staple Line Reinforcement

Regulation Number: 21 CFR 878.3300

Regulation Name: Surgical mesh

Regulatory Class: II Product Code: FTM Dated: January 16, 2004 Received: January 20, 2004

Dear Ms. Mallery:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Miriam C. Provost

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K040119		
Device Name:	Peri-Strips Staple Line Reinforcement	
Indications For Use:		
as : defi	Peri-Strips Staple Line Reinforcement is intended for use as a prosthesis for the surgical repair of soft tissue deficiencies using surgical staplers when staple line reinforcement is needed.	
Peri-Strips can be used for reinforcement of staple lines during lung and bronchus resections and during bariatric surgical procedures.		
Peri-Strips can also be used for reinforcement of staple lines during gastric, small bowel, mesentery, colon, and colorectal procedures.		
Prescription Use AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)		
Concurrence of CDRH, Office of Device Evaluation (ODE)		
Divisio	on Sign-Off) on of General, Restorative, eurological Devices	Page 1 of
510(k)	Number <u>K040119</u>	